Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study (vol 40, pg 3065, 2022).

被引：0
|
作者：
Shen, Lin
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 04期
关键词：
D O I：
10.1200/JCO.23.02629
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：486 / 486
页数：1
相关论文
共 50 条
  • [21] RATIONALE-302: Tislelizumab vs chemotherapy as secondline treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): Impact on health-related quality of life (HRQoL) in Asian patients
    Kim, S-B.
    Van Cutsem, E.
    Ajani, J. A.
    Shen, L.
    Barnes, G.
    Ding, N.
    Tao, A.
    Xia, T.
    Zhan, L.
    Kato, K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1464 - S1464
  • [22] A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).
    Shen, Lin
    Ajani, Jaffer A.
    Kim, Sung-Bae
    Van Cutsem, Eric
    Guo, Baohong
    Song, James
    Paton, Virginia
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
    Chen, Pingyu
    Fu, Chang
    Shen, Lin
    Fei, Zhengyang
    Luo, Mengjie
    Chen, Yanqiu
    Li, Hongchao
    BMC HEALTH SERVICES RESEARCH, 2024, 24 (01)
  • [24] RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
    Yoon, H.
    Kato, K.
    Raymond, E.
    Hubner, R.
    Shu, Y.
    Pan, Y.
    Jiang, Y.
    Zhang, J.
    Park, S.
    Kojima, T.
    Lin, C.
    Gotovkin, E.
    Wyrwicz, L.
    Ishihara, R.
    Li, L.
    Tao, A.
    Shi, J.
    Wang, L.
    Xu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S375 - S375
  • [25] Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma
    Xuyuan Li
    Wen Lin
    Hongbiao Wang
    Wenzhao Lin
    Suiling Lin
    Yingcheng Lin
    Medical Oncology, 2013, 30
  • [26] Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma
    Li, Xuyuan
    Lin, Wen
    Wang, Hongbiao
    Lin, Wenzhao
    Lin, Suiling
    Lin, Yingcheng
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [27] Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
    Gu, Yinfang
    Zou, Xiaofang
    Zhu, Junlin
    Wu, Guowu
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2025, 23 (01)
  • [28] Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up
    Yoon, Harry H.
    Kato, Ken
    Raymond, Eric
    Hubner, Richard
    Shu, Yongqian
    Pan, Yueyin
    Jiang, Yi
    Zhang, Jingdong
    Park, Sook Ryun
    Kojima, Takashi
    Lin, Chen-Yuan
    Wyrwicz, Lucjan S.
    Tougeron, David
    Ishihara, Ryu
    Li, Liyun
    Wu, Hongqian
    Peng, Yanyan
    Yan, Shican
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma
    Yoon, Harry H.
    Kato, Ken
    Hubner, Richard
    Raymond, Eric
    Tao, Aiyang
    Liu, Sumei
    Qazi, Ibrahim
    Xu, Jian-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [30] Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
    Xu, Jianming
    Li, Yi
    Fan, Qingxia
    Shu, Yongqian
    Yang, Lei
    Cui, Tongjian
    Gu, Kangsheng
    Tao, Min
    Wang, Xiuwen
    Cui, Chengxu
    Xu, Nong
    Xiao, Juxiang
    Gao, Quanli
    Liu, Yunpeng
    Zhang, Tao
    Bai, Yuxian
    Li, Wei
    Zhang, Yiping
    Dai, Guanghai
    Ma, Dong
    Zhang, Jingdong
    Bai, Chunmei
    Huang, Yunchao
    Liao, Wangjun
    Wu, Lin
    Chen, Xi
    Yang, Yan
    Wang, Junye
    Ji, Shoujian
    Zhou, Hui
    Wang, Yan
    Ma, Zhuo
    Wang, Yanqi
    Peng, Bo
    Sun, Jiya
    Mancao, Christoph
    NATURE COMMUNICATIONS, 2022, 13 (01)
12345